Abstract:Background: The study of high-throughput genomic profiles from a pharmacogenomics viewpoint has provided unprecedented insights into the oncogenic features modulating drug response. A recent study screened for the response of a thousand human cancer cell lines to a wide collection of anti-cancer drugs and illuminated the link between cellular genotypes and vulnerability. However, due to essential differences between cell lines and tumors, to date the translation into predicting drug response in tumors remains challenging. Recently, advances in deep learning have revolutionized bioinformatics and introduced new techniques to the integration of genomic data. Its application on pharmacogenomics may fill the gap between genomics and drug response and improve the prediction of drug response in tumors. Results: We proposed a deep learning model to predict drug response (DeepDR) based on mutation and expression profiles of a cancer cell or a tumor. The model contains three deep neural networks (DNNs), i) a mutation encoder pre-trained using a large pan-cancer dataset (The Cancer Genome Atlas; TCGA) to abstract core representations of high-dimension mutation data, ii) a pre-trained expression encoder, and iii) a drug response predictor network integrating the first two subnetworks. Given a pair of mutation and expression profiles, the model predicts IC50 values of 265 drugs. We trained and tested the model on a dataset of 622 cancer cell lines and achieved an overall prediction performance of mean squared error at 1.96 (log-scale IC50 values). The performance was superior in prediction error or stability than two classical methods (linear regression and support vector machine) and four analog DNN models of DeepDR, including DNNs built without TCGA pre-training, partly replaced by principal components, and built on individual types of input data. We then applied the model to predict drug response of 9059 tumors of 33 cancer types. Using per-cancer and pan-cancer settings, the model predicted both known, including EGFR inhibitors in non-small cell lung cancer and tamoxifen in ER+ breast cancer, and novel drug targets, such as vinorelbine for TTN-mutated tumors. The comprehensive analysis further revealed the molecular mechanisms underlying the resistance to a chemotherapeutic drug docetaxel in a pan-cancer setting and the anti-cancer potential of a novel agent, CX-5461, in treating gliomas and hematopoietic malignancies. Conclusions: Here we present, as far as we know, the first DNN model to translate pharmacogenomics features identified from in vitro drug screening to predict the response of tumors. The results covered both well-studied and novel mechanisms of drug resistance and drug targets. Our model and findings improve the prediction of drug response and the identification of novel therapeutic options.

ITNR: Inversion Transformer-based Neural Ranking for cancer drug recommendations

Precision Anti-Cancer Drug Selection via Neural Ranking

TCR: A Transformer Based Deep Network for Predicting Cancer Drugs Response

DeepTTA: a transformer-based model for predicting cancer drug response

Personalised Drug Identifier for Cancer Treatment with Transformers using Auxiliary Information

A Novel Approach For Drug Response Prediction In Cancer Cell Lines Via Network Representation Learning

DRN-CDR: A cancer drug response prediction model using multi-omics and drug features

Deep learning methods for drug response prediction in cancer: Predominant and emerging trends

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

NeuMF: Predicting Anti-cancer Drug Response Through a Neural Matrix Factorization Model

NeuRank: Learning to Rank with Neural Networks for Drug–target Interaction Prediction

NeRD: a multichannel neural network to predict cellular response of drugs by integrating multidimensional data

Drug Selection via Joint Push and Learning to Rank

Drug Response Prediction of Liver Cancer Cell Line Using Deep Learning

A novel heterogeneous network-based method for drug response prediction in cancer cell lines

DRPreter: Interpretable Anticancer Drug Response Prediction Using Knowledge-Guided Graph Neural Networks and Transformer

Iterative sure independent ranking and screening for drug response prediction

Apriori prediction of chemotherapy response in locally advanced breast cancer patients using CT imaging and deep learning: transformer versus transfer learning

DeepDRA: Drug repurposing using multi-omics data integration with autoencoders

IRnet: Immunotherapy response prediction using pathway knowledge-informed graph neural network

NerLTR-DTA: Drug-Target Binding Affinity Prediction Based on Neighbor Relationship and Learning to Rank